Literature DB >> 29802425

Response to the letter to the Editor regarding Zeukeng et al.'s article A comparison of new drugs approved by the FDA, the EMA, and Swissmedic: an assessment of the international harmonization of drugs.

Minette-Joëlle Zeukeng1, Enrique Seoane-Vazquez2, Pascal Bonnabry3,4.   

Abstract

Mesh：

Year:  2018        PMID： 29802425     DOI： 10.1007/s00228-018-2486-5

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  5 in total

1.  Market withdrawal of new molecular entities approved in the United States from 1980 to 2009.

Authors:  Zaina P Qureshi; Enrique Seoane-Vazquez; Rosa Rodriguez-Monguio; Kurt B Stevenson; Sheryl L Szeinbach
Journal:  Pharmacoepidemiol Drug Saf       Date:  2011-05-14       Impact factor: 2.890

2.  Priority review drugs approved by the FDA and the EMA: time for international regulatory harmonization of pharmaceuticals?

Authors:  Saad Alqahtani; Enrique Seoane-Vazquez; Rosa Rodriguez-Monguio; Tewodros Eguale
Journal:  Pharmacoepidemiol Drug Saf       Date:  2015-05-27       Impact factor: 2.890

3.  The race for drug approvals: hasten slowly?

Authors:  Alain Braillon
Journal:  Eur J Clin Pharmacol       Date:  2018-05-22       Impact factor: 2.953

4.  A comparison of new drugs approved by the FDA, the EMA, and Swissmedic: an assessment of the international harmonization of drugs.

Authors:  Minette-Joëlle Zeukeng; Enrique Seoane-Vazquez; Pascal Bonnabry
Journal:  Eur J Clin Pharmacol       Date:  2018-02-22       Impact factor: 2.953

Review 5.  A Comparative Review of Marketing Authorization Decisions in Switzerland, the EU, and the USA.

Authors:  Simon Dalla Torre Di Sanguinetto; Esa Heinonen; Janine Antonov; Claus Bolte
Journal:  Ther Innov Regul Sci       Date:  2018-04-19       Impact factor: 1.778
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.